Indication

High density lipoprotein deficiency

High density lipoprotein deficiency (hypoalphalipoproteinemia) is a lipid metabolism disorder characterized by abnormally low circulating levels of high-density lipoprotein cholesterol (HDL-C). Read more about High density lipoprotein deficiency

30 drugs 29 manufacturers

Advertisement

Drugs that treat it

Common High density lipoprotein deficiency therapies.

Showing 10–18 of 30 drugs

NIACIN ER (niacin)

NIACIN/NIACINAMIDE (VITAMIN B-3)·HYPERCHOLESTEROLEMIA·+6
SUN PHARMA GLOB

NIACIN

NIACIN/NIACINAMIDE (VITAMIN B-3)·HYPERCHOLESTEROLEMIA·+6
21ST CENTURY HE

NIACIN ER (niacin)

NIACIN/NIACINAMIDE (VITAMIN B-3)·HYPERCHOLESTEROLEMIA·+6
Amneal Pharmaceuticals

NIACIN ER (niacin)

NIACIN/NIACINAMIDE (VITAMIN B-3)·HYPERCHOLESTEROLEMIA·+6
GSK Consumer Healthcare

NIACOR (niacin)

NIACIN/NIACINAMIDE (VITAMIN B-3)·HYPERCHOLESTEROLEMIA·+6
AVONDALE PHARMA

NIACIN ER (niacin)

NIACIN/NIACINAMIDE (VITAMIN B-3)·HYPERCHOLESTEROLEMIA·+6
Lannett Company

NIACIN ER (niacin)

NIACIN/NIACINAMIDE (VITAMIN B-3)·HYPERCHOLESTEROLEMIA·+6
AUROBINDO PHARM
Filter & compare in the drug finder →Opens the drug finder with High density lipoprotein deficiency preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About High density lipoprotein deficiency.

High density lipoprotein deficiency (hypoalphalipoproteinemia) is a lipid metabolism disorder characterized by abnormally low circulating levels of high-density lipoprotein cholesterol (HDL-C).

Primarily affecting the cardiovascular system, this metabolic state impairs reverse cholesterol transport, significantly increasing the risk of accelerated atherosclerosis and premature coronary artery disease.

It may occur as an acquired condition secondary to insulin resistance, obesity, smoking, or medications, or arise as a primary genetic disorder caused by mutations in genes such as *ABCA1*, *APOA1*, or *LCAT* (as seen in familial HDL deficiency, Tangier disease, and lecithin-cholesterol acyltransferase deficiency).

Depending on the underlying genetic etiology, defining clinical features range from isolated, marked reductions in serum HDL-C to systemic lipid accumulation manifesting as corneal clouding, hepatosplenomegaly, peripheral neuropathy, and tendon or cutaneous xanthomas.

Personalize your experience

Follow High density lipoprotein deficiency and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it